PSB202

Qilu Puget Sound Biotherapeutics (dba Sound Biologics) · Phase 1 active Small molecule

At a glance

Generic name	PSB202
Sponsor	Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PSB202 CI brief — competitive landscape report
PSB202 updates RSS · CI watch RSS
Qilu Puget Sound Biotherapeutics (dba Sound Biologics) portfolio CI